Currently, the modulatory effects of PD-1 on tumor growth and on immunity have been extensively studied, leading to the development of targeting antibodies such as pembrolizumab, nivolumab, cemiplimab, etc. 47, 48. The gene discussed is PDCD1; the disease is neoplasm.